Suchergebnisse - "Chau, Ian"

PubPharm (33)

1

Pembrolizumab as a first-line treatment for advanced gastric cancer

enthalten in: The Lancet. Oncology | 2023

von Chau, I.

2

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02) : primary and updated analyses from a single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2023

von Van Cutsem, E. | di Bartolomeo, M. | Smyth, E. | +13

3

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

enthalten in: Leukemia & lymphoma | 2022

von Halwani, A. | Panizo, C. | Isufi, I. | +21

4

Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

enthalten in: Expert opinion on investigational drugs | 2022

von Lote, H. | Chau, I.

5

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer : 2-year update of the randomized phase 3 KEYNOTE-061 trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2022

von Fuchs, C. | Özgüroğlu, M. | Bang, Y. | +17

6

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

enthalten in: JAMA oncology | 2021

von Chao, J. | Fuchs, C. | Shitara, K. | +19

CommentIn: JAMA Oncol. 2021 Jun 1;7(6):902-903. - PMID 33792611

7

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Herbst, R. | Arkenau, H. | Bendell, J. | +13

8

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein : patient-reported outcomes across two randomised clinical trials

enthalten in: ESMO open | 2020

von Zhu, A. | Nipp, R. | Finn, R. | +13

9

Rationale and design of the POLEM trial : avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

enthalten in: ESMO open | 2020

von Lau, D. | Kalaitzaki, E. | Church, D. | +14

10

Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies : Case series and short literature review

enthalten in: Current problems in cancer | 2019

von Michalarea, V. | Fontana, E. | Garces, A. | +7